Karelis, Thomas

Karelis, Thomas was paid $1.04M by Medicaid between Dec 2019 and Dec 2024, across 24 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 30% of everything it billed.

33Billing provider infoKARELIS, THOMAS
HAZARD, KY 41701

33aNPI1053324129assigned 08/13/2006

33bProvider typeInternal Medicine Physician

28Total paid$1.04M

24GClaims31,702

24DCodes billed24

24AFirst – last monthDec 2019 – Dec 2024

Compared with peers

Next to other Internal Medicine Physician providers in Kentucky

Rank by total paid#32 of 231

Median peer was paid$77K

This provider vs. median14×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	143	$37.57
2020	7,209	$276K
2021	7,779	$232K
2022	6,314	$176K
2023	5,911	$209K
2024incomplete	4,346	$149K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	30%	12,537	10,326	$314K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	17%	1,158	1,100	$173K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	16%	6,432	5,392	$170K
27096		14%	542	450	$141K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	8.1%	1,133	1,042	$84K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	6.8%	1,783	1,526	$70K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	4.5%	2,303	2,008	$47K
72131		1.4%	89	87	$14K
72192		<1%	75	73	$9K
72125	Computed tomography, cervical spine; without contrast material	<1%	34	33	$6K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	791	716	$6K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	57	53	$3K

12 more codes

J1030	Injection, methylprednisolone acetate, 40 mg	<1%	344	$2K
20552		<1%	43	$806.40
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	331	$443.17
S0020	Injection, bupivicaine hydrochloride, 30 ml	<1%	655	$219.14
36415	Collection of venous blood by venipuncture	<1%	78	$16.90
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	176	$4.98
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	<1%	822	$1.22
J3490	Unclassified drugs	<1%	101	$1.06
G9583	Patients prescribed opiates for longer than six weeks	<1%	811	$0.01
G8730	Pain assessment documented as positive using a standardized tool and a follow-up plan is documented	0%	439	$0.00
G9578	Documentation of signed opioid treatment agreement at least once during opioid therapy	0%	825	$0.00
G9562	Patients who had a follow-up evaluation conducted at least every three months during opioid therapy	0%	143	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.